Oramed announces publication in diabetes journal
JERUSALEM — Oramed Pharmaceuticals, a developer of oral drug delivery solutions, has published an article in the Journal of Diabetes Science and Technology’s November issue describing evaluation of the company’s glucagon-like peptide (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.
GLP-1 and its analogs harbor significant therapeutic potential for management of Type 2 diabetes mellitus through their broad physiological impact on glucose regulation-related mechanisms. To date, these drugs are only available in injectable forms, leading to systemic effects upon administration as well as unsatisfactory patient compliance and adherence.
Oramed has applied its oral drug delivery platform to the GLP-1 analog family of medications. High sugar-content meals were delivered to animals in the presence or absence of ORMD-0901, followed by close monitoring of blood glucose levels. Specific formulations were found to effectively blunt expected glucose surges in both ORMD-0901-treated pigs and canines. The two animal models used for testing the performance of ORMD-0901 indicated retained drug activity when delivered using Oramed’s oral drug delivery platform.
Oramed already has started clinical testing of its ORMD-0901 product to test the formulation’s safety and efficacy in healthy individuals. Further testing and development are expected to significantly contribute to current diabetes control options and success rates.
To view the article abstract, click here.
Decision Resources: Type 2 diabetes market in China to nearly double by 2014
BURLINGTON, Mass. — A growing drug-treated population will cause the Type 2 diabetes drug market in China to increase to $2.5 billion by 2014, according to a new report by Decision Resources.
The Type 2 diabetes market in China totaled $1.4 billion in 2009, Decision Resources said.
"China now has the largest Type 2 diabetes patient population in the world, and is the third-largest market for Type 2 diabetes agents behind the United States and Japan," said Decision Resources analyst Jing Wu. "The Type 2 diabetes market in China will continue to grow between 2009 and 2014 at an annual rate of 13%, which is faster than expected growth in the United States or Japan."
Decision Resources also noted that while metformin continues to be the most widely prescribed agent in China because of its low cost, newly launched DPP-IV inhibitors, such as Merck’s Januvia, Novartis’s Galvus and Bristol-Myers Squibb/AstraZeneca’s Onglyza, as well as GLP-1 analogues, including Novo Nordisk’s Victoza and Eli Lilly/Amylin/Alkerme’s Bydureon, will be used more frequently.
CVS Caremark receives PBM, DTM accreditation from URAC
WOONSOCKET, R.I. — CVS Caremark announced on Thursday that it has been awarded pharmacy benefit management and drug therapy management accreditation from URAC, a healthcare accrediting organization that establishes quality standards for the healthcare industry. CVS Caremark previously had received accreditation for PBM and DTM from URAC in 2007.
"CVS Caremark is pleased to receive these accreditations," stated Per Lofberg, head of CVS Caremark’s PBM business. "This provides further validation of the company’s ongoing focus and commitment to patient care, outstanding customer service and overall quality."
URAC offers the only third-party, voluntary accreditation program of this scope for the PBM and prescription services industry. All standards were developed by URAC’s Pharmacy Advisory Committee, which includes stakeholders, employers, consumers, pharmacy consultants, health plans, retail pharmacy, PBM organizations, pharmacy professional organizations, labor and large public purchasing groups.
"By applying for and receiving URAC accreditation, CVS Caremark has demonstrated a commitment to quality health care," added Alan Spielman, URAC president and CEO. "Quality health care is crucial to our nation’s welfare, and it is important to have organizations that are willing to measure themselves against national standards and undergo rigorous evaluation by an independent accrediting body."